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Abstract
Background: Type I hypersensitivity is characterized by the overreaction of the immune system against otherwise 
innocuous substances. It manifests as allergic rhinitis, allergic conjunctivitis, allergic asthma or atopic dermatitis if mast 
cells are activated in the respective organs. In case of systemic mast cell activation, life-threatening anaphylaxis may 
occur. Currently, type I hypersensitivities are treated either with glucocorticoids, anti-histamines, or mast cell stabilizers. 
Although these drugs exert a strong anti-allergic effect, their long-term use may be problematic due to their side-
effects.
Results: In the course of a routine in vitro screening process, we identified beta-escin as a potentially anti-allergic 
compound. Here we tested beta-escin in two mouse models to confirm this anti-allergic effect in vivo. In a model of the 
early phase of allergic reactions, the murine passive cutaneous anaphylaxis model, beta-escin inhibited the effects of 
mast cell activation and degranulation in the skin and dose-dependently prevented the extravasation of fluids into the 
tissue. Beta-escin also significantly inhibited the late response after antigen challenge in a lung allergy model with 
ovalbumin-sensitized mice. Allergic airway inflammation was suppressed, which was exemplified by the reduction of 
leucocytes, eosinophils, IL-5 and IL-13 in the bronchoalveolar lavage fluid. Histopathological examinations further 
confirmed the reduced inflammation of the lung tissue. In both models, the inhibitory effect of beta-escin was 
comparable to the benchmark dexamethasone.
Conclusions: We demonstrated in two independent murine models of type I hypersensitivity that beta-escin has 
potent anti-allergic properties. These results and the excellent safety profile of beta-escin suggest a therapeutic 
potential of this compound for a novel treatment of allergic diseases.
Background
The prevalence of allergic diseases, such as allergic rhini-
tis, allergic conjunctivitis, allergic asthma, food allergies
and anaphylaxis has constantly increased in the devel-
oped world during the last decades [1,2]. These diseases
are caused by a dysfunction of the immune system in
response to normally harmless environmental agents and
are characterized by an excessive activation of mast cells,
basophils and T helper cells of the Th2 linage. Type I
hypersensitivity reactions involve many types of inflam-
matory cells, but mast cells and eosinophils are the two
main effector cell types. The allergic inflammation is
often classified in three temporal phases. In an immediate
early phase allergic reaction, Immunoglobulin E (IgE)
bound to FcεRI on mast cells and basophils is crosslinked
by repeated allergen exposure. Consequently, these cells
release various pre-formed or rapidly synthesized chemi-
cal mediators. These mediators, such as histamine, elicit
vasodilation, increased vascular permeability, oedema
and acute functional changes in affected organs. The IgE-
mediated early phase reaction occurs within minutes of
allergen exposure. It can be either localized with symp-
toms such as rhinitis, conjunctivitis, acute asthma attacks
and hives, or systemic, resulting in a potentially lethal
anaphylactic shock. The following late phase response is
initiated by cytokines and chemokines derived from mast
cells, resulting in recruitment of leukocytes into the
affected tissues [2-5]. In the case of allergic asthma, for
example, the observed clinical symptoms are airway
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oedema, increased mucus production, recurrent bron-
chospasm and sustained inflammation of the tissue by
infiltrating leukocytes. Finally, it may result in a chronic
allergic disease, including tissue damage and remodelling
[6-9].
Type I allergies are commonly treated by corticoster-
oids, anti-histamines and mast cell stabilizers. These
drugs are anti-inflammatory, or block the action of aller-
gic mediators by preventing activation of cells or degran-
ulation processes. Also, bronchodilators are used for the
treatment of allergic asthma. All these therapeutics help
to alleviate the symptoms of allergy but, especially after
long-term and high-dose medication, they can have quite
substantial side-effects. In particular, oral corticosteroids
can cause general immuno-suppression, skin fragility and
Cushing's syndrome, and even new generation anti-hista-
mines are not completely void of sedative effects [10,11].
Therefore, there is still a vital need for the development
of new anti-allergic drugs with satisfactory tolerability for
long-term use. They should be effective on the early as
well as the late phase allergic reactions.
In our laboratory, a series of natural extracts have been
screened  in vitro for their potential anti-inflammatory
and anti-allergic effects. Among these extracts, low con-
centrations of the test substance beta-escin showed an
inhibitory effect in IgE-antigen-stimulated mast cells.
Beta-escin is the main active constituent of Aesculus hip-
pocastanum seed extracts, which is composed of a mix-
ture of triterpene saponins [12]. It is a well known
substance with numerous pharmacologically interesting
effects. Beta-escin was reported to possess anti-inflam-
matory activities, venotonic properties and endothelium-
protectant effects [13] which were supported by different
animal models [14-20]. Furthermore, several clinical
studies demonstrated an excellent tolerability of beta-
escin. Thus, beta-escin is widely used for the treatment of
chronic venous insufficiency, post-operative ileus, haem-
orrhoids, acute impact injuries and is included in cos-
metic products [13,21-24].
However, to date beta-escin has not been described to
prevent or alleviate allergic diseases. In our study we
investigated the anti-allergic efficacy of beta-escin in two
different experimental mouse models of allergy: The pas-
sive cutaneous anaphylaxis (PCA) model is a widely used
in vivo model to examine the anti-allergic effect of com-
pounds on immediate hypersensitivity type I reactions
because it mimics an acute mast cell-mediated reaction
[25,26]. Ovalbumin (OVA)-induced allergic airway
inflammation is a model which exhibits symptoms of
acute allergic asthma. It is caused by a late phase allergic
reaction and is characterized by the inflammation of air-
ways and lung tissue [8,27]. Our results from these in vivo
models show that beta-escin is a highly promising anti-
allergic compound.
Results
Beta-escin significantly reduces the PCA reaction in mice
In the PCA model, skin mast cells are passively sensitized
with antigen-specific IgE and activated by systemic
administration of the corresponding antigen. This leads
to a massive release of allergic mediators and the permea-
bilization of capillary blood vessels. If Evans blue dye is
applied together with the antigen, this effect can be visu-
alized by extravasation of the dye. The extension of the
blue stained skin area is therefore taken as a measure for
the intensity of the early phase of the hypersensitivity
reaction.
To examine the anti-allergic effect of beta-escin in vivo,
we first evaluated the substance in this PCA model. Mice
of the negative control group, which received 0.9%
sodium chloride solution (NaCl) or PBS, developed a
strong PCA reaction (Figure 1A). Five minutes after chal-
lenge the spots of these vehicle-treated mice were already
clearly visible and expanded during the next 10 min. The
mean dimension of the blue spots was 38.8 mm2 ± 1.9
SEM at 15 min after antigen application, which was con-
sidered as 100% response. In the positive control group,
mice were treated with 3 mg/kg dexamethasone, which is
typically used as reference compound in allergic animal
models [28]. The appearance of blue spots at the sensi-
tized skin areas of dexamethasone-treated mice was
delayed, and the areas were significantly smaller in com-
parison to the vehicle control group. At 15 min the blue
spots measured only 58.3% compared to the vehicle con-
trol (Figure 1A). Strikingly, treatment with 3 mg/kg beta-
escin also strongly suppressed the PCA reaction. The
mean area of the blue spots at 15 min was limited to 17.4
mm2 ± 2.0 SEM, representing only 44.7% of the mean area
from vehicle-treated animals (Figure 1A). This indicated
that beta-escin inhibited the anaphylactic reaction more
potently than dexamethasone. Considering the different
molecular masses of both compounds, this efficacy of
beta-escin is particularly remarkable. The molecular
mass of beta-escin is 1137.3 g/mol, which is 2.8-fold
higher than the molecular mass of dexamethasone (392.5
g/mol). Therefore, our results with 3 mg/kg of each com-
pound suggest that beta-escin inhibits the PCA reaction
more than 3-fold better than dexamethasone when com-
paring molar concentrations.
The anti-allergic property of beta-escin is dose dependent
In the next experiment, we examined the dose-depen-
dence of the anti-allergic effects of beta-escin in the PCA
mouse model. Beta-escin was applied at dosages of 1.0,
1.5, 2.0, 2.5 and 3.0 mg/kg 6 h prior challenge. Beta-escinLindner et al. BMC Immunology 2010, 11:24
http://www.biomedcentral.com/1471-2172/11/24
Page 3 of 10
significantly suppressed the extravasation of Evans blue
into skin tissue in a dose-dependent manner (Figure 1B).
The lowest tested dose of 1.0mg/kg showed no effect on
the PCA reaction yet. Starting at a concentration of
1.5 mg/kg of beta-escin, an inhibitory effect became
detectable. The application of 2.0 and 2.5 mg/kg beta-
escin strongly inhibited the PCA reactions, which
resulted in statistically significant reductions by 21.8%
and 44.8%, respectively, when compared to the vehicle-
treated group. The strongest effect was seen with the
dose of 3 mg/kg, which reduced the reaction by 55.3%.
These results clearly show that the anti-allergic effects
of beta-escin are dose-dependent.
Effects of beta-escin after different periods of pre-
treatment in the murine PCA model
To determine the influence of the pre-treatment period
on the PCA reaction, mice were injected with 3mg/kg
beta-escin 1, 2, 3 or 6 h before induction of PCA (Figure
2). After pre-treatment for 1 h, beta-escin already inhib-
ited the reaction by 39.1% compared to the vehicle group.
The effect increased to 57.4% inhibition of the PCA reac-
tion after pre-treatment for 2 h. At the 3 h and 6 h time
points, the response was inhibited by 48.5% and 55.3%,
respectively. Longer periods of pre-treatment (12 or 15 h)
did not further improve the efficacy of beta-escin (data
not shown). In conclusion, beta-escin significantly inhib-
ited the PCA reaction at every tested time point in com-
parison to the negative control group. The course of this
treatment response is consistent with the reported phar-
macokinetic properties of beta-escin where a maximal
serum level was reached after 2 h and the half-life was
calculated to be 6 to 8 h [13].
This series of experiments in the PCA model strongly
suggested that beta-escin is beneficial for the treatment
of immediate type I hypersensitivity reactions and ana-
phylaxis. Therefore, it was of great interest to expand our
studies to an additional model which reflects the late
phase of an allergic response, such as a murine model of
allergic airway inflammation.
Beta-escin reduces the infiltration of total leukocytes and 
eosinophils into the airways in a murine model of allergic 
airway inflammation
To determine whether beta-escin has effects on allergic
airway inflammation, OVA-sensitized mice were chal-
Figure 1 Anti-allergic and dose-dependent efficacy of beta-escin 
in the murine PCA model. For PCA induction, anti-TNP IgE (2.5 μg) 
was injected intradermally into the dorsal skin at 6 independent spots. 
After 15 min, mice were challenged with intravenous injection of 50 μg 
DNP-BSA supplemented with 1% Evans blue dye. Blue stained skin ar-
eas were quantified from digital photographs 15 min after challenge. 
(A) SKH1-mice were pre-treated i.p. with vehicle (10 ml/kg, n = 21), 
dexamethasone (dex, 3 mg/kg, n = 5) or beta-escin (escin, 3 mg/kg, n 
= 12) 6 h prior application of antigen. (B) Different concentrations of 
beta-escin (n = 4-12) were given i.p. 6 h prior challenge. For each 
mouse the mean of 6 spots was calculated. Based on these values the 
mean ± SEM was determined for each group, normalized to the vehi-
cle control group (equals 100%) and represented as column or point in 
the graphs (A) and (B), respectively. Significant differences between 
the treatment groups and the vehicle group are indicated with: * p < 
0.05 and *** p < 0.001.
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Figure 2 Effects of beta-escin at different time points of pre-treat-
ment in the murine PCA model. SKH1-mice were injected with beta-
escin (3 mg/kg) at different time points prior PCA induction as de-
scribed in Fig. 1. For each mouse the mean of 6 spots was calculated. 
Based on these values the mean ± SEM was determined for 4 - 12 (es-
cin) or 21 (vehicle) mice per treatment group and normalized to the 
vehicle control group. Significant differences between the treatment 
groups and the vehicle group are indicated with: ** p < 0.01 and *** p 
< 0.001.
0
20
40
60
80
100
120
1h 2h 3h 6h
vehicle escin treatment (time prior challenge)
a
r
e
a
 
(
%
)

 
Lindner et al. BMC Immunology 2010, 11:24
http://www.biomedcentral.com/1471-2172/11/24
Page 4 of 10
lenged with aerosol containing either OVA antigen or the
vehicle control PBS. Total cell infiltration, eosinophilia
and Th2-cytokine secretion was then determined in the
Broncho Alveolar Lavage Fluids (BALFs) of these mice. In
the positive control group (PBS-treated mice), OVA chal-
lenge caused a marked increase of inflammatory cells in
the BALF, especially eosinophils, which reflects the inten-
sity of airway inflammation and the extent of cell infil-
trates into the lungs. This was absent in the PBS-
challenged negative control group (Figures 3A and 3B). In
these experiments, dexamethasone was again used as a
reference drug. A dosage of 1 mg/kg dexamethasone once
a day was selected on the basis of its molecular mass
( w h i c h  is  2 . 8 - f o l d  l e s s  t h a n  o f  be t a - e s ci n ,  as  d is cus s ed
above), based on our own preliminary experiments, and
previous reports [29,30]. This reference compound pre-
vented cell infiltration into the airways by 56.6% at 40 h
(Figure 3A).
Based on the results of the PCA model, a dose of 3 mg/
kg beta-escin was administered twice daily to maintain
the serum level of beta-escin during the challenge period.
The number of total BAL cells was significantly
decreased in the beta-escin-treated group in comparison
to the PBS-treated group, resulting in a reduction by
49.5% at 40 h after the last challenge (Figure 3A). More-
over, both beta-escin and dexamethasone treatment sig-
nificantly reduced the number of eosinophils in the
BALF. Beta-escin treatment potently inhibited eosinophil
infiltration into the airways by approximately 61.7% at 40
h (Figure 3B). Our findings indicate that beta-escin
reduces airway inflammation and prevents eosinophil
infiltration into the airways in this allergy model.
Beta-escin reduces the release of asthma-associated 
cytokines in BALF
Th2-associated cytokines are typically released in allergic
airway reactions. To evaluate the effects of beta-escin on
cytokine secretion, the levels of IL-5 and IL-13 were
determined in BALF supernatants of individual mice
f r o m  e a c h  g r o u p .  I t  w a s  previously demonstrated in
kinetic studies that the release of different types of cytok-
ines into BALF of asthmatic mice peaks at different time-
points. The maximal secretion ranged from as early as 2 -
4 h for TNF-alpha to 8 - 12 h, with a long lasting eleva-
tion, for IL-5 and IL-13 [31]. Based on this study we
decided to perform the collection of BALF for the evalua-
tion of IL-5 and IL-13 cytokines at 15 h after the last chal-
lenge. As shown in Figures 4A and 4B, IL-5 and IL-13
levels from OVA-challenged and PBS-treated mice of the
positive control group were markedly increased com-
pared to the negative control group (challenged and
treated with PBS). The high concentration of IL-5 (126.6
± 11.4 pg/ml) of the positive control group was signifi-
cantly reduced by beta-escin treatment (90.0 ± 10.8 pg/
ml), which was comparable to the reduction achieved by
dexamethasone treatment (73.2 ± 12.8 pg/ml). Similarly,
the IL-13 concentration was reduced to 35.8 ± 4.4 pg/ml
by beta-escin treatment, which represented an inhibitory
effect of 43.8% compared to the positive control group
(63.7 ± 9.5 pg/ml). Again this effect was comparable to
the reference compound, because dexamethasone
reduced the IL-13 concentration to 28.2 ± 7.0 pg/ml
(inhibition of 55.7%).
Figure 3 Beta-escin reduces total cells and eosinophil recruit-
ment in an OVA-induced model of allergic airway inflammation. 
BALB/c mice were sensitized with OVA on days 0, 14 and 21. The aero-
sol challenges with OVA or PBS were performed twice a day on days 28 
and 29. 40 h after the last aerosol challenge, the mice were sacrificed 
for the analyses of the airway inflammation of the lungs. Groups were 
treated as follows: control group = PBS-challenged, treated with PBS; 
PBS group = OVA-challenged, treated with PBS; dex group = OVA-chal-
lenged, treated with dexamethasone (1 mg/kg, once a day) and escin 
group = OVA-challenged, treated with beta-escin (3 mg/kg, twice a 
day). Groups were compared with respect to the total cell counts (A) 
and the number of eosinophils (B) in the BALFs. Each bar represents 
the mean of 13 - 21 mice from 4 independent, but identical experi-
ments ± SEM out of a series of similar experiments. Significant differ-
ences of the dex and escin groups to the PBS group are indicated with: 
** p < 0.01 and *** p < 0.001.
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These results indicate that beta-escin successfully sup-
presses the secretion of Th2-cytokines into the airways of
OVA-challenged mice.
Beta-escin reduces the infiltration of inflammatory cells 
into lung tissue
To further examine the effects of beta-escin on lung
pathology, histological analyses of lung sections were per-
formed. Lung tissue was collected 40 h after the last aero-
sol challenge and analyzed by an experienced pathologist
who was blinded to the sample identity to ensure an unbi-
ased evaluation. To quantify the observed changes in lung
tissue, inflammation and eosinophil scorings were calcu-
lated for each mouse sample from all 4 experimental
groups, examples of which are presented in Figures 5A -
D. In comparison to the negative control group, the lung
histology from PBS-treated and OVA-challenged mice
showed intense inflammatory cell infiltrates containing
lymphocytes, neutrophils, macrophages and to a large
extent eosinophils in the peribronchiolar and perivascu-
lar connective tissue (Figures 5A and 5B). Dexametha-
sone treatment attenuated the inflammatory cell
infiltration in the lung tissue (Figure 5C). As expected,
also beta-escin significantly reduced inflammation in
lung tissue. In particular, the infiltration of eosinophils
was suppressed compared to the PBS group (Figure 5D).
Figure 5E summarizes the scoring for inflammation and
eosinophilia for the individual treatment groups and
highlights the statistical significance of the improvements
by beta-escin or dexamethasone treatment.
These inhibitory effects of both drugs are in agreement
with the determined cell types and numbers in the BALFs
and confirm that beta-escin exerts an ameliorating effect
on the inflammation in the airways and also in the lung
tissue.
Discussion
This report presents the first study of the effect of the
natural triterpene saponin beta-escin on the early and
late phases of type I hypersensitivity in vivo. Our results
demonstrate that beta-escin strongly inhibits allergic
reactions. A benchmark comparison indicates that beta-
escin is comparable or even superior to dexamethasone, a
standard reference compound for the evaluation of anti-
allergic and anti-inflammatory drugs.
We first pinpointed the anti-allergic effect of beta-escin
in the murine PCA model, where beta-escin potently
suppressed the localized mast cell-mediated allergic reac-
tion. The evaluation of a series of pre-treatment periods
showed that the protective effect of beta-escin lasted at
least for 6 h, which is consistent with published pharma-
cokinetic data [13]. Moreover, the PCA inhibition was
strictly dose-dependent, which confirmed the pharmaco-
logically relevant dose-response correlation of beta-escin
with the reduction of symptoms.
In the model of acute allergic airway inflammation we
could show that beta-escin effectively suppressed also the
late phase allergic response. Beta-escin exerted beneficial
effects on airway and lung inflammation by reducing leu-
kocyte infiltration and eosinophilia in the lungs. In addi-
tion, it significantly decreased the release of Th2-specific
cytokines into the BALF, as exemplified by IL-5 and IL-13
measurements.
Th2-cytokines play a pivotal role in the pathogenesis of
asthma. The cytokine IL-5 initiates the terminal differen-
tiation, proliferation, migration and activation of eosino-
phils [6,8]. IL-13 can also regulate the recruitment of
eosinophils to the airways through its various effects on
epithelial cells and smooth muscle cells [32]. Consistent
with the reduction of these cytokines, the recruitment of
inflammatory cells, especially of eosinophils, was mark-
Figure 4 Beta-escin reduces cytokine production in an OVA-in-
duced model of allergic airway inflammation. BAL fluid was collect-
ed 15 h after the last OVA-challenge from sensitized BALB/c mice of 
the 4 different treatment groups as described in Fig. 3. (A) IL-5 and (B) 
IL-13 levels in the BALF of individual mice from each group were deter-
mined by ELISA. Each bar represents the mean of 11 - 16 mice from 3 
independent, but identical experiments ± SEM out of a series of similar 
experiments. Significant differences of the dex and escin groups to the 
PBS group are indicated with: * p < 0.05 and ** p < 0.01.
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edly suppressed in the BALF by beta-escin treatment.
The histo-pathological examination showed milder
pathology, reduced inflammatory cell infiltrates and a
lower density of eosinophils in the lungs of beta-escin-
treated mice, which further supported our results from
the BALF analysis. Eosinophils release a number of cyto-
toxic proteins, such as major basic protein, platelet acti-
vating factor and leukotrienes, which are responsible for
the characteristic damage of the airway epithelium in
allergic asthma [33,34]. The reduction of eosinophil
recruitment to the pulmonary tissue by beta-escin is
Figure 5 Beta-escin reduces inflammation and eosinophilia in lungs of mice from the allergic airway inflammation model. Representative 
photomicrographs in a 20 and 60 times magnification (inset) of H&E stained lung sections from 40 h after the last challenge show the lung parenchy-
ma and the peribronchial and perivascular infiltration of inflammatory cells from (A) PBS-challenged mice treated with PBS (negative control); (B) OVA-
challenged mice treated with PBS (= positive control); (C) OVA-challenged mice treated with dexamethasone (1 mg/kg, once a day) and (D) OVA-
challenged mice treated with beta-escin (3 mg/kg, twice a day). The arrows indicate representative eosinophils in the infiltrate. (E) Semi-quantitative 
analyses of peribronchial and perivascular inflammatory cells and percentage of eosinophils in lung sections were performed with a scoring system. 
Each value represents the mean of 13 - 21 mice from 4 independent, but identical experiments ± SEM out of a series of similar experiments. Significant 
differences of the dex and escin groups to the PBS group are indicated in brackets.
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therefore pivotal to minimize tissue damage and/or
improve recovery.
Airway inflammation constitutes a key symptom in the
pathogenesis of asthma. Therefore, strategies which
inhibit this initial phase may be regarded as a promising
treatment approach [2,9,34]. Nonetheless, asthma is
characterized as a chronic airway disease, which includes
airway obstruction and remodelling of lung tissue. Nowa-
days, inhaled corticosteroids (ICS) are the primarily used
agents for treating persistent asthma. Whereas several
and sometimes serious side effects are observed for oral
corticosteroids, ICS minimize systemic exposure and are
typically well tolerated. However, a number of asthma
patients are resistant to treatments with ICS or even to
oral glucocorticoids [35]. This clearly indicates a medical
need for the development of alternative anti-asthmatic
drugs with good tolerability. Previously it was shown that
extracts of Diplotropis ferruginea, Ganoderma tsugae
and ginseng attenuate allergic airway inflammation in
murine asthma models [29,36,37]. Ginseng for example
was effective in resolving chronic histo-pathological
changes in the lungs [29]. However, despite the low inci-
dence of toxicity of ginseng, adverse reactions, such as
insomnia, hypertension and diarrhoea have been
reported [29].
For beta-escin, one case of occupational asthma related
to beta-escin inhalation is described [38]. This patient
was exposed to low-doses of beta-escin daily for 30 years
and the onset of symptoms occurred 20 years after the
initial exposure. While this case appears to be a singular
incidence, it cautions that beta-escin may not be recom-
mended for an aerosol inhalation therapy. Oral adminis-
tration of beta-escin is a preferred and safe alternative,
and it is not expected that oral treatment with beta-escin
on clinical demand will cause or exacerbate asthma.
Patients suffering from venous insufficiencies have been
treated with beta-escin for more than 30 years, without a
report of an increase in allergies.
Generally, beta-escin is considered to have a very low
level of adverse reactions. A very low incidence of toxic
effects has been observed in clinical trials using well-
characterized preparations [13], which is highly encour-
aging for the further development of beta-escin towards
an alternative to current allergy medications.
Future perspective
We have shown that beta-escin is highly potent if applied
by intraperitoneal administration. In view of a clinical
application in humans in the future, further application
routes, such as oral and intranasal, will be examined in
models of allergy. An intranasal application may be suit-
able for the localized treatment of allergic rhinitis if a
droplet size is generated that precludes aerosol inhalation
to the lungs. A systemic treatment by oral application
may be preferred for patients with asthma.
In order to investigate if a therapeutic application of
beta-escin is equally effective for the control or reversion
of pulmonary pathologies and the remodelling of lung tis-
sue at a late stage of the disease, additional studies of
long-term treatment with beta-escin in a chronic asthma
model are planned. To receive more insight into the mode
of action, further research is required to explain the influ-
ence of beta-escin on intracellular signaling cascades in
mast cells, such as mitogen- or stress-activated protein
kinase pathways, on calcium influx and on transcription
factors such as NF-κB and NF-AT [3,39,40], and on the
stabilization of membranes. A very recent study showed
that beta-escin can impair the NF-κB-signaling cascade
in cancer cell lines [41]. Considering the key role of NF-
κB in immune responses and inflammation, it is an
intriguing possibility that beta-escin inhibits allergic
reactions by interfering with NF-κB-signaling in a similar
manner. Elucidating the molecular mode of action of
beta-escin will support the further development of beta-
escin as anti-allergic medication.
Conclusions
The results of our studies indicate that beta-escin pro-
vides a highly effective treatment against early as well as
late phase allergic responses in two different in vivo mod-
els for type I hypersensitivity reactions. Considering the
beneficial effect seen in our experiments and the excel-
lent tolerability and safety profiles proven in several ani-
mal models and human clinical studies, beta-escin has an
exciting therapeutic potential for the treatment of allergic
inflammatory diseases such as allergic rhinitis and aller-
gic asthma in humans. Therefore, clinical trials are
planned to confirm our observations also in patients who
suffer from allergies.
Methods
Animals
Specific pathogen-free SKH1-mice (strain 313, hairless,
Charles River, Germany), were used for the PCA model,
and BALB/c mice (Harlan, Italy) for the asthma model.
All mice were maintained under standard laboratory con-
ditions in the animal facility of the Veterinary University
Vienna. All experimental procedures were discussed and
approved by the institutional ethics committee and per-
formed under the Austrian experimental animal license
numbers 68.205/0134-C/GT/2007 and 68.205/0206-II/
10b/2008.
Test and reference compounds
Beta-escin (CAS No. 6805-41-0; Euro OTC, Germany,
and Nobilus Ent, Poland) and water-soluble dexametha-
sone (CAS No. 50-02-2; Sigma-Aldrich, Austria) wereLindner et al. BMC Immunology 2010, 11:24
http://www.biomedcentral.com/1471-2172/11/24
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dissolved in 0.9% sodium chloride (NaCl; Mayrhofer,
Austria) or in phosphate buffered saline (PBS; PAA, Aus-
tria) in indicated concentrations for intraperitoneal (i.p.)
administration.
Passive Cutaneous Anaphylaxis model
Hairless SKH1-mice, female, 10 weeks old, were pre-
treated i.p. with beta-escin, dexamethasone (3 mg/kg) or
vehicle (NaCl or PBS, 10 ml/kg) at different dosages and
time points prior induction of a PCA reaction as indi-
cated in the text and figure legends. To initiate the PCA
reaction, 2.5 μg anti-TNP IgE (BioLegend, Austria)
diluted in 10 μl of 0.9% NaCl solution was intradermally
injected into the dorsal skin at 6 independent spots per
animal. Fifteen minutes after sensitization, the mice were
challenged by intravenous injection of 0.1 ml 0.9% NaCl
containing 50 μg of DNP-BSA (Calbiochem, Austria) and
1% Evans blue (Sigma-Aldrich, Austria). Mice were sacri-
ficed 15 min after DNP-BSA injection and their dorsal
skin was removed for measurement of the extension of
the blue stained skin areas by analysis of digital photos
using ImageJ software (1.39 d version; NIH; http://
rsb.info.nih.gov/ij/) [25]. The effects of beta-escin and
dexamethasone were expressed in percent of mean values
of the vehicle control samples.
Induction of allergic airway inflammation and treatment 
schedule
Female BALB/c mice, 6 - 8 weeks old, were divided into
four groups (n = 10 - 13 animals per group). All mice were
immunized on days 0, 14 and 21 by i.p. injections of 10 μg
of OVA (Grade V, Sigma-Aldrich, Austria) and 2 mg of
Al(OH)3 (Pierce, USA) suspended in 0.2 ml of PBS. On
days 28 and 29 after the initial immunization, animals
were challenged for 60 min twice daily with 1% OVA dis-
solved in PBS and aerosolized by an ultrasonic nebulizer
(Kendall Aerodyne 18605, Covidien, Austria). Negative
control mice were treated in parallel with PBS aerosol
only. 15 or 40 h after the last challenge (days 30 and 31),
the mice were sacrificed, and allergic airway inflamma-
tion was characterized. The 4 treatment groups were as
follows: control group (negative control group) = chal-
lenged with PBS and treated with PBS (10 ml/kg, twice a
day, i.p.), PBS group (positive control group) = challenged
with OVA and treated with PBS as vehicle control (10 ml/
kg, twice a day, i.p.), beta-escin group = challenged with
OVA and treated with beta-escin (3 mg/kg, twice a day,
i.p.), and dex group = challenged with OVA and treated
w i t h  d e x a m e t h a s o n e  ( 1m g / k g ,  o n c e  a  d a y ,  i . p . ) .  T h e
treatments started on day 27 and ended on day 30 for the
assessment at 15 h and on day 31 for the assessment at 40
h after the last aerosol challenge.
The presence of OVA-specific IgE antibodies in the
sera of all OVA-immunized mice was verified by an OVA-
ELISA kit (MD Biosciences, USA) to ensure that the
observed differences in the treatment groups were indeed
specific to the respective treatments and not caused by
lack of OVA-specific reactions due to a failed immuniza-
tion.
BAL for determination of cell counts, leukocyte 
differentiation and cytokine levels
To perform BAL, animals were anaesthetized and a 23-
gauge cannula was inserted into the trachea. 1 ml of ice-
cold PBS was instilled with a syringe and recovered by
gentle aspiration. The recovered BALF was centrifuged
(150 × g at 4°C for 5 minutes) and the supernatant was
recovered for the determination of cytokines in the BALF.
The cell pellet was resuspended in 0.5 ml ice-cold PBS.
The total and differential cell counts were determined by
the automatic cell counter ADVIA 120 (Bayer Diagnos-
tics, Austria). Cytokines in BALF supernatants were mea-
sured by ELISA for IL-5 (BioLegend, Austria) and IL-13
(BenderMedSystems, Austria) according to the manufac-
turer's instructions. The detection limit for IL-5 and IL-
13 was 7.8 pg/ml.
Histological assessment of inflammation and eosinophils in 
lung tissue
Mice were sacrificed 40 h after the last aerosol challenge.
Following the collection of blood and BAL, the lung tis-
sues were removed, fixed in 7% neutral-buffered formalin
solution, embedded in paraffin, cut in 3 μm sections, and
stained with Hematoxylin & Eosin (H&E) for examining
the cell infiltration.
Lung tissues were evaluated by an experienced patholo-
gist who had been blinded to the treatment groups. The
degree of peribronchiolar and perivascular inflammation
was evaluated semi-quantitatively by a scoring system
which was defined by the number of peribronchiolar
inflammatory cells: 0 = no cells; 1 = a few cells; 2 = a ring
of cells 1 cell layer deep; 3 = a ring of cells 2-4 cells deep; 4
= a ring of cells >4 cells deep [42]. The percentage of
eosinophils from the inflammatory cells was determined
and categorized from 0 to 4: 0 = no eosinophils; 1 = 25%,
2 = 25 - 50%; 3 = 50 - 75% and 4 = > 75% of inflammatory
cells.
Statistical analysis
Data were expressed as the mean ± standard error of the
mean (SEM), checked for normal distribution and their
statistical significance was determined by Student's two-
tailed t-test for independent means, using SPSS (PASW
Statistics 17.0). P < 0.05 was considered to be statistically
significant.
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